	US 12,311,031 B2
	Antibodies specific to CD44
Shaofei Zhang, Shanghai (CN); Bing Hou, Shanghai (CN); Guangcun Cheng, Shanghai (CN); Shu-Hui Liu, Redwood City, CA (US); and Xun Meng, Shanghai (CN)
Assigned to Multitude Inc., Shanghai (CN)
Filed by Multitude Inc., Shanghai (CN)
Filed on Jul. 27, 2021, as Appl. No. 17/386,197.
Application 17/386,197 is a continuation of application No. PCT/US2020/014425, filed on Jan. 21, 2020.
Claims priority of application No. PCT/CN2019/073402 (WO), filed on Jan. 28, 2019.
Prior Publication US 2022/0049008 A1, Feb. 17, 2022
Int. Cl. A61K 47/68 (2017.01); A61K 38/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); A61K 35/00 (2006.01)

CPC A61K 47/6849 (2017.08) [A61K 47/68031 (2023.08); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2884 (2013.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)]

19 Claims

1. An isolated antibody that binds to human CD44, wherein the antibody comprises a heavy chain variable region (V_H) comprising a heavy chain complementary determining region 1 (HC CDR1) of the amino acid sequence of SEQ ID NO: 2, a HC CDR2 of the amino acid sequence of SEQ ID NO: 3, and a HC CDR3 of the amino acid sequence of SEQ ID NO: 4, and a light chain variable region (V_L) comprising a light chain CDR1 (LC CDR1) of the amino acid sequence of SEQ ID NO: 5, a LC CDR2 of the amino acid sequence of SEQ ID NO: 6, and a LC CDR3 of the amino acid sequence of SEQ ID NO: 7.